Login Register Cart 0
Generic placeholder image

Current Drug Discovery Technologies

Editor-in-Chief

ISSN (Print): 1570-1638
ISSN (Online): 1875-6220

Back
Journal Home About Journal Editorial Board Journal Insight Current Issue Volumes/Issues
Subscribe
Review Article

Aripiprazole: An FDA Approved Bioactive Compound to Treat Schizophrenia- A Mini Review

Author(s): Arvind Kumar*, Harpreet Singh, Amrita Mishra and Arun K. Mishra

Volume 17, Issue 1, 2020

Page: [23 - 29] Pages: 7

DOI: 10.2174/1570163815666181008151718

Price: $65

Open Access Journals Promotions 2
conference banner
Abstract

Objective: Aripiprazole, a synthetic compound, obtained by chemical modification of the structure of quinolinone is considered as an atypical antipsychotic drug. The present review is an attempt to summarize the updated information related to reported chemistry and pharmacology of Aripiprazole.

Development: Aripiprazole, under development by Otsuka Pharmaceutical, was approved by the U.S. Food and Drug Administration (USFDA) by the end of 2002 with an aim to treat patients with schizophrenia. This drug got approved by European Commission in February 2013 to treat the patients having severe manic episodes in bipolar I disorder Additionally, it got approval in Japan in January 2006 and in Canada in 2014.

Pharmacology: Aripiprazole shows high specificity for dopamine receptor especially D2 and D3, serotonin 5-HT1A and serotonin 5-HT2A receptors, reasonable specificity for dopamine D4, serotonin 5- HT2C and 5-HT7, alpha1-adrenergic and histamine H1 receptors. It also shows moderate specificity for the serotonin reuptake. The major side effects include headache, agitation, akithesia, anxiety, tachycardia, insomnia, postural hypotension, constipation, vomiting, dizziness, nervousness and somnolence.

Conclusion: The present article embarks the available information on Aripiprazole with emphasis on its clinical pharmacology, mechanism of action, pharmacokinetics, pharmacodynamics, metabolism and clinical trials.

Keywords: Schizophrenia, aripirazole, quinolinone, clinical trials, bioactive compound, neurological disorders.

Graphical Abstract

[1]
Krivoy A, Fischel T, Weizman A. [The cognitive deficit in schizophrenia]. Harefuah 2012; 151(5): 277-280, 319.
[PMID: 22844731]
[2]
Patel KR, Cherian J, Gohil K, Atkinson D. Schizophrenia: overview and treatment options. P&T 2014; 39(9): 638-45.
[PMID: 25210417]
[3]
Lewis DA, Lieberman JA. Catching up on schizophrenia: natural history and neurobiology. Neuron 2000; 28(2): 325-34.
[http://dx.doi.org/10.1016/S0896-6273(00)00111-2] [PMID: 11144342]
[4]
Diagnostic and Statistical Manual of Mental Disorders. 4th ed., text revision. Washington, D.C.: American Psychiatric Association 2000; pp. 297-343.
[5]
Schultz SH, North SW, Shields CG. Schizophrenia: a review. Am Fam Physician 2007; 75(12): 1821-9.
[PMID: 17619525]
[6]
Macht DL. Contributions to psychopharmacology. Johns Hopkins Hosp Bullet 1920; 31: 167-73.
[7]
Laborit H, Huguenard P, Alluaume R. Un nouveau stabilisateur végétatif; le 4560 RP. Presse Med 1952; 60(10): 206-8.
[PMID: 14957790]
[8]
Meyer JM, Simpson GM. From chlorpromazine to olanzapine: a brief history of antipsychotics. Psychiatr Serv 1997; 48(9): 1137-9.
[http://dx.doi.org/10.1176/ps.48.9.1137] [PMID: 9285972]
[9]
Baldessarini RJ, Frankenburg FR. Clozapine. A novel antipsychotic agent. N Engl J Med 1991; 324(11): 746-54.
[http://dx.doi.org/10.1056/NEJM199103143241107] [PMID: 1671793]
[10]
Wang B, Franklin JM, Eddings W, Landon J, Kesselheim AS, Did FDA. Decisionmaking affect anti-psychotic drug prescribing in children?: A Time-Trend Analysis Plos 2016; 1-12.
[11]
Burda K, Czubak A, Kus K, Nowakowska E, Ratajczak P, Zin J. Influence of aripiprazole on the antidepressant, anxiolytic and cognitive functions of rats. Pharmacol Rep 2011; 63(4): 898-907.
[http://dx.doi.org/10.1016/S1734-1140(11)70605-3] [PMID: 22001977]
[12]
Thase ME, Jonas A, Khan A, et al. Aripiprazole monotherapy in nonpsychotic bipolar I depression: results of 2 randomized, placebo-controlled studies. J Clin Psychopharmacol 2008; 28(1): 13-20.
[http://dx.doi.org/10.1097/jcp.0b013e3181618eb4] [PMID: 18204335]
[13]
Chue P, Chue J. A review of aripiprazole long-acting injection. Curr Med Res Opin 2016; 32(3): 441-52.
[http://dx.doi.org/10.1185/03007995.2015.1123145] [PMID: 26713457]
[14]
Tanioka T, Fuji S, Kataoka M, et al. Retrospective study of japanese patients with schizophrenia treated with aripiprazole. International Scholarly Research Network 2012; pp. 1-7.
[15]
Health Canada Approves Otsuka and Lundbeck's Abilify Maintena®(Aripiprazole Once Monthly) as Treatment for Bipolar I Disorder in Adults. https://www.businesswire.com/news/ home/20171102006599/en/Health-Canada-Approves-Otsuka-Lundbecks-Abilify-Maintena%C2%AE
[16]
Oshiro Y, Sato S, Kurahashi N, et al. Novel antipsychotic agents with dopamine autoreceptor agonist properties: synthesis and pharmacology of 7-[4-(4-phenyl-1-piperazinyl)butoxy]-3,4-dihydro-2(1H)-quinolinone derivatives. J Med Chem 1998; 41(5): 658-67.
[http://dx.doi.org/10.1021/jm940608g] [PMID: 9513593]
[17]
Kikuchi T, Tottori K, Uwahodo Y, et al. 7-(4-[4-(2,3-Dichlorophenyl)-1-piperazinyl]butyloxy)-3,4-dihydro-2(1H)-quinolinone (OPC-14597), a new putative antipsychotic drug with both presynaptic dopamine autoreceptor agonistic activity and postsynaptic D2 receptor antagonistic activity. J Pharmacol Exp Ther 1995; 274(1): 329-36.
[PMID: 7616416]
[18]
Les A, Badowska-Roslonek K. laszcz M, Duda AK, Baran P, Kaczmarek L. Optimization of aripiprazole synthesis. Acta Polon Pharma Drug Res 2010; 67(2): 151-7.
[19]
Bingwen J, Hui S, Zhengda Z. Zhangjiagang Jiugu Technology Co, Ltd 2012; 1-7.
[20]
Yokoi F, Gründer G, Biziere K, et al. Dopamine D2 and D3 receptor occupancy in normal humans treated with the antipsychotic drug aripiprazole (OPC 14597): a study using positron emission tomography and [11C]raclopride. Neuropsychopharmacology 2002; 27(2): 248-59.
[http://dx.doi.org/10.1016/S0893-133X(02)00304-4] [PMID: 12093598]
[21]
Zajdel P, Marciniec K, Maślankiewicz A, et al. Antidepressant and antipsychotic activity of new quinoline- and isoquinoline-sulfonamide analogs of aripiprazole targeting serotonin 5-HT1A/5-HT2A/5-HT7 and dopamine D2/D3 receptors. Eur J Med Chem 2013; 60: 42-50.
[http://dx.doi.org/10.1016/j.ejmech.2012.11.042] [PMID: 23279866]
[22]
Ge HX, Wang LC, Jiang ZZ, Ni SL. Synthesis and bioactivity of aripiprazole derivatives. Arzneimittelforschung 2006; 56(10): 673-7.
[PMID: 17225561]
[23]
Avram S, Berner H, Milac AL, Wolschann P. Quantitative structure – activity relationship studies on membrane receptors inhibition by antipsychotic drugs. Application to schizophrenia treatment. Monatsh Chem 2008; 139: 407-26.
[http://dx.doi.org/10.1007/s00706-007-0782-3]
[24]
Gründer G, Fellows C, Janouschek H, et al. Brain and plasma pharmacokinetics of aripiprazole in patients with schizophrenia: An [18F]fallypride PET study. Am J Psychiatry 2008; 165(8): 988-95.
[http://dx.doi.org/10.1176/appi.ajp.2008.07101574] [PMID: 18381901]
[25]
FDAU. Drug approval package, Abilify (aripiprazole) intramuscularinjectable solution. 2006.http: //www.accessdata. fda.gov/scripts/cder/drugsatfda/index.cfm?fuseaction=Search.DrugDetails
[26]
Mallikaarjun S, Salazar DE, Bramer SL. Pharmacokinetics, tolerability and safety of aripiprazole following single and multiple oral dose administration. Eur Neuropsychopharmacol 2000; 10(Suppl. 3): 306-7.
[http://dx.doi.org/10.1016/S0924-977X(00)80351-X]
[27]
FDA U. Inventor drug approval package, Abilify (aripiprazole) tablets. http://www.accessdata.fda.gov/scripts/cder/drugsatfda/index.cfm?fuseaction=Search.DrugDetails2002
[28]
McGavin JK, Goa KL. Aripiprazole. CNS Drugs 2002; 16(11): 779-86.
[http://dx.doi.org/10.2165/00023210-200216110-00008] [PMID: 12383035]
[29]
Kubo M, Koue T, Maune H, Fukuda T, Azuma J. Pharmacokinetics of aripiprazole, a new antipsychotic, following oral dosing in healthy adult Japanese volunteers: influence of CYP2D6 polymorphism. Drug Metab Pharmacokinet 2007; 22(5): 358-66.
[http://dx.doi.org/10.2133/dmpk.22.358] [PMID: 17965519]
[30]
Carson W, McQuade R, Saha A, Torbeyns A, Stock E. Aripiprazole versus placebo for re-lapse prevention in patients with chronic schizophrenia. Eur Neuropsychopharmacol 2002; 12: S288-8.
[http://dx.doi.org/10.1016/S0924-977X(02)80404-7]
[31]
Potkin SG, Saha AR, Kujawa MJ, et al. Aripiprazole, an antipsychotic with a novel mechanism of action, and risperidone vs placebo in patients with schizophrenia and schizoaffective disorder. Arch Gen Psychiatry 2003; 60(7): 681-90.
[http://dx.doi.org/10.1001/archpsyc.60.7.681] [PMID: 12860772]
[32]
ABILIFY. https://www.accessdata.fda.gov/ drugsatfda_docs/label/2014/021436s038,021713s030,021729s022
[33]
Citrome L, Josiassen R, Bark N, Brown KS, Mallikaarjun S, Salazar DE. Pharmacocinetics and safety of aripiprazole and concomitant mood stabilizers. Int J Neuropsychopharmacol 2002; 5(Suppl. I): S187-92.
[34]
Argo TR, Carnahan RM, Perry PJ. Aripiprazole, a novel atypical antipsychotic drug. Pharmacotherapy 2004; 24(2): 212-28.
[http://dx.doi.org/10.1592/phco.24.2.212.33145] [PMID: 14998222]
[35]
Jamróz W, Kurek M, Łyszczarz E, et al. 3D printed orodispersible films with Aripiprazole. Int J Pharm 2017; 533(2): 413-20.
[http://dx.doi.org/10.1016/j.ijpharm.2017.05.052] [PMID: 28552800]
[36]
Kim Y, Jeon JY, Chung YC, Kim MG. Pharmacokinetics of a new orally disintegrating tablet formulation of aripiprazole 15 mg administered without water in healthy middle-aged korean subjects. Clin Ther 2015; 37(12): 2772-9.
[http://dx.doi.org/10.1016/j.clinthera.2015.10.006] [PMID: 26546405]
[37]
Kane JM, Carson WH, Saha AR, et al. Efficacy and safety of aripiprazole and haloperidol versus placebo in patients with schizophrenia and schizoaffective disorder. J Clin Psychiatry 2002; 63(9): 763-71.
[http://dx.doi.org/10.4088/JCP.v63n0903] [PMID: 12363115]
[38]
Di S G, Riva MA. Aripiprazole: from pharmacological profile to clinical use. Neuropsychiatr Dis Treat 2015; 11: 2635-47.
[39]
Wojnicz A, Belmonte C, Koller D, et al. Effective phospholipids removing microelution-solid phase extraction LC-MS/MS method for simultaneous plasma quantification of aripiprazole and dehydro-aripiprazole: Application to human pharmacokinetic studies. J Pharm Biomed Anal 2018; 151: 116-25.
[http://dx.doi.org/10.1016/j.jpba.2017.12.049] [PMID: 29324280]
[40]
Mohan T, Dolan S, Mohan R, Dawson J. Aripiprazole and impulse-control disorders in high-risk patients. Asian J Psychiatr 2017; 27: 67-8.
[http://dx.doi.org/10.1016/j.ajp.2017.02.015] [PMID: 28558898]
[41]
Calabrese JR, Sanchez R, Jin N, et al. Symptoms and functioning with aripiprazole once-monthly injection as maintenance treatment for bipolar I disorder. J Affect Disord 2018; 227(227): 649-56.
[http://dx.doi.org/10.1016/j.jad.2017.10.035] [PMID: 29174738]
[42]
Gholampour H, Moezi L, Shafaroodi H. Aripiprazole prevents renal ischemia/reperfusion injury in rats, probably through nitric oxide involvement. Eur J Pharmacol 2017; 813: 17-23.
[http://dx.doi.org/10.1016/j.ejphar.2017.07.032] [PMID: 28734929]
[43]
Yoo S, Kim MY, Cho JY. Syk and Src-targeted anti-inflammatory activity of aripiprazole, an atypical antipsychotic. Biochem Pharmacol 2018; 148: 1-12.
[http://dx.doi.org/10.1016/j.bcp.2017.12.006] [PMID: 29241811]
[44]
Łaszcz M, Witkowska A. Studies of phase transitions in the aripiprazole solid dosage form. J Pharm Biomed Anal 2016; 117: 298-303.
[http://dx.doi.org/10.1016/j.jpba.2015.09.004] [PMID: 26397209]
[45]
Freeman E, Lin J, Chow S, Davis C, Li M. Sex differences in aripiprazole sensitization from adolescence to adulthood. Pharmacol Biochem Behav 2017; 156: 39-47.
[http://dx.doi.org/10.1016/j.pbb.2017.04.001] [PMID: 28389140]
[46]
Masand S, Sherwood R, Aitchison KJ. P03-88 - An increase in bone stability in an aripiprazole add-on or switching study. Eur Psychiatry 2011; 26(1): 1257.
[http://dx.doi.org/10.1016/S0924-9338(11)72962-5]

Rights & Permissions Print Cite
Article Metrics
82
2
Wayfinder Image
Open Access Journals Promotions
© 2024 Bentham Science Publishers | Privacy Policy